A5053472875- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Transplantation: Methods and Outcomes
- Heart Failure Treatment and Management
- Cardiac Arrest and Resuscitation
- Cardiac pacing and defibrillation studies
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiovascular Function and Risk Factors
- Cardiac Valve Diseases and Treatments
- Congenital Heart Disease Studies
- Parathyroid Disorders and Treatments
- Fuel Cells and Related Materials
- Renal Transplantation Outcomes and Treatments
- Organ Transplantation Techniques and Outcomes
- Cardiac Fibrosis and Remodeling
- Viral Infections and Immunology Research
- Nutrition and Health in Aging
- Health Systems, Economic Evaluations, Quality of Life
- Cardiomyopathy and Myosin Studies
- Pulmonary Hypertension Research and Treatments
- Healthcare Decision-Making and Restraints
- Potassium and Related Disorders
- Hemodynamic Monitoring and Therapy
- Eosinophilic Disorders and Syndromes
- Neuroendocrine Tumor Research Advances
Cleveland Clinic
2017-2024
Cleveland Clinic Florida
2022-2024
Cleveland Foundation
2022-2023
Cleveland Clinic Lerner College of Medicine
2021-2023
Houston Methodist
2010-2021
Case Western Reserve University
2021
University of Rochester Medical Center
2021
University School
2021
Methodist Hospital
2010-2019
Methodist Hospital
2014-2018
In an early analysis of this trial, use a magnetically levitated centrifugal continuous-flow circulatory pump was found to improve clinical outcomes, as compared with mechanical-bearing axial pump, at 6 months in patients advanced heart failure.
Data for left ventricular assist devices (LVADs) in patients with noninotrope-dependent heart failure (HF) are limited. The goal of this study was to evaluate HeartMate II (HMII) LVAD support versus optimal medical management (OMM) ambulatory New York Heart Association functional class IIIB/IV meeting indications destination therapy but not dependent on intravenous inotropic support. This a prospective, multicenter (N = 41), observational 200 (97 LVAD, 103 OMM). Entry criteria included ≥1...
The authors sought to provide the pre-specified primary endpoint of ROADMAP (Risk Assessment and Comparative Effectiveness Left Ventricular Assist Device Medical Management in Ambulatory Heart Failure Patients) trial at 2 years.The was a prospective nonrandomized observational study 200 patients (97 with left ventricular assist device [LVAD], 103 on optimal medical management [OMM]) that showed survival improved functional status 1 year better LVADs compared OMM patient population ambulatory...
Doppler echocardiography is currently applied for the assessment of left ventricular and right hemodynamics in patients with cardiovascular disease. However, there are conflicting reports about its accuracy unstable decompensated heart failure. The objective this study was to evaluate technique failure.Consecutive failure had simultaneous invasively by echocardiography. In 79 patients, noninvasive measurements stroke volume (r=0.83, P<0.001), pulmonary artery systolic P<0.001) diastolic...
Background: The MOMENTUM 3 study (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3) has demonstrated that the (HM3) pump is associated with reduced strokes compared II (HMII) device. We now perform a comprehensive analysis stroke events to evaluate their longitudinal occurrence, clinical correlates, patterns, and impact on outcome across 2-year duration support. Methods: randomized controlled trial HM3 centrifugal-flow...
Background Limited information exists on the role of B‐cell‐dependent mechanisms in progression heart failure ( HF ). However, failing human myocardium, there is evidence deposition activated complement components as well anticardiac antibodies. We aimed to determine contribution B‐cells using a nonsurgical mouse model nonischemic cardiomyopathy CMP Methods and Results protocol involved use l ‐ NAME NaCl drinking water angiotensin‐ II infusion for 35 days. At day 35, mice were analyzed by...
Clinical trials inform on average efficacy, but individualized risk assessments for outcome prediction are important in guiding treatment implementation.The authors developed and validated a patient-specific score to predict survival at 1 2 years after HeartMate 3 (HM3) left ventricular assist device (LVAD) implantation.The MOMENTUM (Multicenter Study of MagLev Technology Patients Undergoing Mechanical Circulatory Support Therapy with 3) trial includes 2,200 HM3 LVAD patients the pivotal...
In the MOMENTUM 3 (Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3) pivotal trial, (HM3) fully magnetically levitated left ventricular assist device (LVAD) demonstrated superiority over axial-flow II (HMII) LVAD. The patterns and predictors hospitalizations HM3 LVAD have not been characterized. This study sought to determine causes, predictors, impact during support. discharged after implantation were analyzed. 485...